MED12 and prostate carcinoma: These findings align with those of 4 cohorts of primary prostate cancer tissues (TCGA_PRAD, GSE62872, GSE21034, and GSE46691), which showed a significant positive correlation between MED12 and c-MYC mRNA expression (Fig. 2D).